Abstract
The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis. In addition to glomerulonephritis and a butterfly rash, previously negative tests for antinuclear, anti-dsDNA and anti-Sm antibodies became positive. We assume that rIFN-gamma induced the de novo development of SLE in our patient.
MeSH terms
-
Adult
-
Antibodies / analysis
-
Antibodies, Antinuclear / analysis
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Autoantigens / analysis
-
Female
-
Glomerulonephritis / complications
-
Humans
-
Immunoblotting
-
Interferon-gamma / adverse effects*
-
Interferon-gamma / therapeutic use
-
Lupus Erythematosus, Systemic / chemically induced*
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / immunology
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Ribonucleoproteins, Small Nuclear*
-
Time Factors
-
snRNP Core Proteins
Substances
-
Antibodies
-
Antibodies, Antinuclear
-
Autoantigens
-
Recombinant Proteins
-
Ribonucleoproteins, Small Nuclear
-
snRNP Core Proteins
-
Interferon-gamma